Recombinant Human IL-2 Protein, GMP grade, HPLC-verified

概述

产品介绍

Cat No. IL-2-PH2001

库存：现货

Size

点击咨询在线客服

产品介绍

纯度

≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

内毒素

< 5 EU per mg of the protein.

生物活性

1. Measured in a cell proliferation assay using CTLL2. The ED₅₀ for this effect is typically 1-8 ng/mL. The specific activity of recombinant human IL-2 is approximately 20,000 IU/μg.
2. Using the Octet RED System, the affinity constant (Kd) of IL2 Protein, Human, Recombinant (Cat. GMP-11848-HNAE) bound Anti-IL2 Antibody (Cat. 11848-MM03) was 0.1 nM.

蛋白构建

A DNA sequence encoding the mature form of human IL2 (P60568-1) (Ala 21-Thr 153) was expressed and purified with an initial Met.

Accession#

P60568-1

表达宿主

E. coli

种属

Human

预测 N 端

Met

分子量

The recombinant human IL-2 consists of 134 amino acids and predicts a molecular mass of 15.5 kDa.

缓冲液

Supplied as sterile 20mM HAc-NaAc+0.004% Tween-80 pH 4.0
Please contact us for any concerns or special requirements.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

运输方式

Liquid. It is shipped out with blue ice.

稳定性 & 储存条件

Samples are stable for up to thirty-six months from date of receipt at -20℃ to -80℃.Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

复溶

To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA.

Using the Octet RED System, the affinity constant (Kd) of IL2 Protein, Human, Recombinant (Cat. GMP-11848-HNAE) bound Anti-IL2 Antibody (Cat. 11848-MM03) was 0.1 nM.

Measured in a cell proliferation assay using CTLL2. The ED₅₀ for this effect is typically 1-8 ng/mL. The specific activity of recombinant human IL-2 is approximately 20,000 IU/μg.

Recombinant Human IL-2 Protein, GMP grade, HPLC-verified: 别称

IL-2 Protein, Human; lymphokine Protein, Human; TCGF Protein, Human

IL-2 背景信息

Interleukin-2, also known as a T-cell growth factor, TCGF, and IL2, is a secreted protein that belongs to the IL-2 family. Interleukin-2 / IL-2 was the first interleukin molecule to be discovered. Interleukin-2 / IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2 / IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2 / IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells). Interleukin-2 / IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2 / IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2 / IL-2 and the expression of IL-2 receptors IL-2R. The IL-2 / IL-2R interaction then stimulates the growth, differentiation, and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2 / IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2 / IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2 / IL-2 for clinical use is manufactured by Chiron Corporation. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2 / IL-2 in HIV therapy is ineffective.

全称

interleukin 2

研究领域

Neuroinflammation